Eupraxia Cash and Short-term Investments Reach $138.9 Million
The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the end of the Q4 of 2025. These funds are being used to fund clinical trials in EP-104GI and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes. "The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new treatment for Eosinophilic Esophagitis," said James A. Helliwell, CEO of Eupraxia. "With the capital from the recent financing, we are excited to continue development of EP-104GI in EoE and accelerate additional clinical programs in new indications within the GI field, where we believe that EP-104GI has the opportunity to work due to the Diffusphere's ability to provide hyper-targeted delivery into diseased areas over a long period of time without the typical systemic exposure profile."
